Inflammatory myofibroblastic tumour (IMT)

What changed: Inflammatory myofibroblastic tumour (IMT)

Every dated change on the records linked to Inflammatory myofibroblastic tumour (IMT), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval1Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-10This recordInflammatory myofibroblastic tumour (IMT)
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 2

2018 · 1

2018MilestoneCrizotinib
EORTC 90101 CREATE phase 2
Schöffski and colleagues, Lancet Respir Med: high response rate in ALK-positive IMT.

2010 · 1

2010MilestoneInflammatory myofibroblastic tumour (IMT)
Crizotinib response in ALK-positive IMT
Butrynski and colleagues, NEJM case report.

1999 · 1

1999MilestoneInflammatory myofibroblastic tumour (IMT)
ALK rearrangements found in IMT
Griffin and colleagues identify 2p23 rearrangements, the first ALK fusions outside lymphoma.

1939 · 1

1939MilestoneInflammatory myofibroblastic tumour (IMT)
First description as inflammatory pseudotumour of the lung
A milestone in how this cancer is treated.